Publications

Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis.

Blum K, Modestino EJ, Neary J, Gondré-Lewis MC, Siwicki D, Moran M, Hauser M, Braverman ER, Baron D, Steinberg B, Laughlin TM, Badgaiyan RD; Biomed J Sci Tech Res. 2018 Jan 7;2(2):1-4.

Insurance Companies Fighting the Peer Review Empire without any Validity: the Case for Addiction and Pain Modalities in the face of an American Drug Epidemic.

Blum K, Jacobs W, Modestino EJ, DiNubile N, Baron D, McLaughlin T, Siwicki D, Elman I, Moran M, Braverman ER, Thanos PK, Badgaiyan RD; SEJ Surg Pain. 2018 Oct 4;1(1):1-11.

Hypothesizing the Coupling of DNA-Guided Precision, Pro-Dopamine Regulation (KB220) with Pharmaceutical Opioid Analgesic Agents to Mitigate Hypodopminergia- Induced Hyperalgesia: the Induction of Transmodulation of Dopaminergic Signaling

Raymond Brewer, MD, Abdalla Bowirrat, MD., PhD., Edward J. Modestino, Ph.D., Thomas McLaughlin, MD., PhD, David Baron, DO, Mark Moran, MD, Sampada Badgaiyan, MD., Rajendra D. Badgaiyan, MD, David Siwickie, MD, Brent Boyett6, DO., Stephen M.Taylor, MD., Eric R. Braverman, MD., Kenneth Blum,* PhD

EC Psychology & Psychiatry; Perspective Invited

High genetic addiction risk score (GARS) in chronically prescribed severe chronic opioid probands attending multi-pain clinics: an open clinical pilot trial

Mark Moran, Kenneth Blum*, Jessica Valdez Ponce, Lisa Lott, Marjorie C. Gondré – Lewis, Brent Boyett, David Siwicki, Thomas Simpatico, Sampada Badgaiyan, Mary Hauser, Raymond Brewer, B. William Downs, Zsolt Demetrovics, Eric R. Braverman, Philip Fynman, Alexander Weingarten, David E. Smith, David Baron, Steve Henriksen, Panayotis K Thanos, Bruce Steinberg, Edward J. Modestino, Rajendra D. Badgaiyan, Igor Elman,Thomas McLaughlin, Mark Gold

Molecular Neurobiology; pending publication

Epigenetic trait evidence for hyperdopaminergic (surfeit) during brain development and genetic state evidence for hypodopaminergia (deficit) in adolescents: nutrigenomic solutions

Kenneth Blum, Bruce Steinberg, Lisa Lott, Jessica Valdez Ponce, Mark Moran, B.W Down, Edward J Modestino, Panayotis K Thanos , Thomas McLaughlin, Marjorie C. Gondre Lewis, David Baron, David Siwicki, Joseph Morgan, Margaret A. Madigan, Raju Hajela, Igor Elman, Debra Barh, Brent Boyett, Arwen Podesta, A. Kenison Roy, Sampoda Badgaiyan, Thomas A. Simpatico, Mary Hauser, Rajendra D. Badgaiyan;  Journal Child & Adolescent Psychopharmacology. 

Rapid Anti-Depressant Relief by Ketamine: Exploring A Complex Mechanism of Action

Kenneth Blum*, Todd C. Pappas, Bryan Clifton, David Baron, Margaret A. Madigan, Lisa Lott, Mark Moran, Cannon Clifton, Scott Worrich, Ervey Clarke, Brent Boyett, Abdalla Bowirrat and Mark S. Gold Current Psychopharmacology; 99 – 112 ( 14 ); [ Vol. 8 , Issue. 2 ].

Precision Behavioral Management (PBM) a Novel Genetically Guided Therapy to Combat Reward Deficiency Syndrome (RDS)

K. Blum, A K. Roy III, A. Podesta, E.J., Modestino, B. Steinberg,  M.C. Gondré -Lewis, D. Baron, P.K, Thanos, L.Lott, J. ValdezPonc, B. Boyett, D. Siwicki, M. Moran, I. Elman, D. Edwards, T. McLaughlin, E.R. Braverman, T. Simpatico, M. Hauser, B.W. Downs, R.D. Badgaiyan
Book Chapter-Cambridge Handbook on SUD and Behavioral Addictions.

Insurance Companies Fighting the Peer Review Empire without any Validity: the Case for Addiction and Pain Modalities in the face of an American Drug Epidemic

K. Blum, W. Jacobs, E.J. Modestino, N. DiNubile, D. Baron, T. McLaughlin, D. Siwicki, I. Elman, M. Moran, E. R. Braverman, P. K. Thanos, R. D. Badgaiyan
SEJ Surg Pain. 2018 Oct 4; 1(1): 1–11.

Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis

Kenneth Blum, Edward J Modestino, Jennifer Neary, Marjorie C Gondré-Lewis, David Siwicki, Mark Moran, Mary Hauser, Eric R Braverman, David Baron, Bruce Steinberg, Thomas Mc Laughlin, Rajendra D Badgaiyan
Biomed J Sci Tech Res. 2018 Jan 7; 2(2): 1–4.

Previous Research Experience

2007-2008:

A Randomized, Double-Blind, Placebo Controlled, Parallel-Group With A Crossover

Confirmation Period Study Of “Study Drug” For The Treatment Of Postherpetic Neuralgia 

2007-2008:

A Randomized, Double-Blind, Active-Controlled Crossover Study To Evaluate The Efficacy And Safety Of “Study Drug” Compared With “Study Drug” For The Management Of Breakthrough Pain In Opioid-Tolerant Patients With Chronic Pain

2007-2008:

Randomized, Double-Blind, Placebo-Controlled Multi-Center Study To Evaluate The Safety

And Efficacy Of “Study Drug” For The Treatment Of Breakthrough Cancer Pain.

Start Your Treatment Today